Table 1.
Patient study group: clinical characteristics and US features.
| US Features | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | Age | Vaccine | Lymph Node Localization | Clinical Presentation | Oncological History | Nm | Size | Form | Cortical Thickening and Hilum | Sonoelasto | SMI | US Follow-Up to 2 Weeks |
| W | 25 | Pfizer | Axillary ipsilateral to vaccine injection | Three days after first dose of vaccine, axillary swelling and pain present. Also hypomobility ipsilateral arm | None | 6 | Variable: from 0.7 cm to 2.8 cm | Ovular | Prev. no hilum evidence | Prevalent hard pattern | Central and peripheral vascular signals | Normalized to 60 days |
| M | 64 | Pfizer | Supraclavicular ipsilateral to vaccine injection | Occasional autopalpation 2 weeks after second dose vaccine | None | 2 | Around 1.0 cm | Ovular | Assimetric cortical thickening with hilum evidence | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |
| W | 28 | Astazeneca | Supraclavicular ipsilateral to vaccine injection | Two days after first dose vaccine, supraclavicular swelling and pain present | None | 3 | Variable: from 0.6 to 1.5 cm | Ovular | No evidence hilum | Prevalent hard pattern | Central and peripheral vascular signals | Normalized to 45 days |
| W | 72 | Astazeneca | Supraclavicular ipsilateral to vaccine injection | One day after first dose vaccine, supraclavicular swelling and pain present | None | 2 | Subcentimetric size | Round | Asimmetric cortical thickening with hilum evidence | Prevalent hard pattern | Peripheral vascular signals | Normalized to 30 days |
| M | 42 | Pfizer | Axillary ipsilateral to vaccine injection | Occasionally 1 weeks after second dose during chest ct | None | 3 | Variable: from 1.5 to 2.0 cm | Ovular | Simmetric cortical thickening with normal hilum | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |
| M | 39 | Astazeneca | Supraclavicular ipsilateral to vaccine injection | Four days after first dose vaccine, supraclavicular swelling and pain present | None | 1 | Subcentimetric size | Round | No evidence hilum | Prevalent hard pattern | Central and peripheral vascular signals | Normalized to 30 days |
| M | 60 | Pfizer | Supraclavicular ipsilateral to vaccine injection | Occasional autopalpation 12 days after second dose vaccine | None | 2 | Around 1.0 cm | Ovular | Simmetric cortical thickening with normal hilum | Stiffness similar to surrounding tissue | Central and peripheral vascular signals | Unnecessary other follow-up |
| W | 49 | Pfizer | Axillary ipsilateral to vaccine injection | Occasionally, 6 days after first dose, during breast sonography for oncological surveillance | Breast cancer 3 years ago | 4 | Variable: from 1.0 to 2.0 cm | Ovular | Asimmetric cortical thickening and poor evidence hilum | Stiffness similar to surrounding tissue | Central and peripheral vascular signals | Unnecessary other follow-up |
| M | 41 | Moderna | Supraclavicular ipsilateral to vaccine injection | Two days after first dose vaccine, supraclavicular swelling and pain present | None | 3 | Subcentimetric size | Ovular | No evidence hilum | Stiffness similar to surrounding tissue | Central and peripheral vascular signals | Normalized to 30 days |
| W | 54 | Pfizer | Axillary ipsilateral to vaccine injection | Occasionally, 14 days after second dose, during breast sonography for surveillance | None | 3 | Variable: from 1.0 to 2.0 cm | Ovular | Simmetric cortical thickening with normal hilum | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |
| W | 74 | Astazeneca | Supraclavicular ipsilateral to vaccine injection | Ten days after first dose vaccine | None | 2 | Subcentimetric size | Ovular | Simmetric cortical thickening with normal hilum | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |
| M | 35 | Pfizer | Supraclavicular ipsilateral to vaccine injection | Day after the first dose vaccine, supraclavicular swelling and pain present | None | 1 | Around 1.5 cm | Round | No evidence hilum | Prevalent hard pattern | Central and peripheral vascular signals | Normalized to 60 days |
| W | 52 | Pfizer | Axillary ipsilateral to vaccine injection | Occasionally during breast sonography for oncological surveillance | None | 3 | Variable: from 1.0 to 2.5 cm. | Ovular | Simmetric cortical thickening with normal hilum | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |
| W | 26 | Astazeneca | Supraclavicular ipsilateral to vaccine injection | 2 days after the first dose vaccine, axillary swelling and pain present | None | 5 | Subcentimetric size | Ovular | No hilum evidence | Prevalent hard pattern | Central and peripheral vascular signals | Normalized to 45 days |
| W | 53 | Pfizer | Axillary ipsilateral to vaccine injection | Occasionally, 16 days after first dose, during breast sonography for oncological surveillance | Breast cancer 2 years ago | 3 | Variable: from 1.0 to 2.0 cm | Ovular | Asimmetric cortical thickening with hilum evidence | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |
| M | 62 | Pfizer | Axillary ipsilateral to vaccine injection | Occasionally, 2 weeks after first dose, during chest ct to monitor small polmonary nodules | None | 3 | Variable: from 1.5 to 2.0 cm. | Ovular | Simmetric cortical thickening with normal hilum | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |
| M | 57 | Pfizer | Axillary ipsilateral to vaccine injection | Occasional autopalpation 2 weeks after second dose vaccine | Kidney cancer 4 years ago | 2 | Around 1.0 cm | Ovular | Asimmetric cortical thickening with hilum evidence | Stiffness similar to surrounding tissue | Normal | Normalized to 30 days |
| W | 69 | Astazeneca | Supraclavicular ipsilateral to vaccine injection | Three days after first dose vaccine | None | 3 | Subcentimetric size | Round | Asimmetric cortical thickening with hilum evidence | Stiffness similar to surrounding tissue | Central and peripheral vascular signals | Unnecessary other follow-up |
| W | 37 | Pfizer | Axillary ipsilateral to vaccine injection | Three days after first dose vaccine, axillary swelling present | Melanoma 5 years ago | 5 | Variable: from 1.5 to 2.0 cm. | Ovular | Assimetric cortical thickening with hilum evidence | Prevalent hard pattern | Central and peripheral vascular signals | Normalized to 45 days |
| M | 63 | Moderna | Axillary ipsilateral to vaccine injection | Occasionally, 16 days after first dose, during mammography | None | 3 | Variable: from 1.5 to 2.0 cm. | Ovular | Simmetric cortical thickening with normal hilum | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |
| F | 32 | Astrazeneca | Supraclavicular ipsilateral to vaccine injection | Day after first dose vaccine, supraclavicular swelling and pain present | None | 1 | Around 1.2 cm | Round | No evidence hilum | Prevalent hard pattern | Central and peripheral vascular signals | Normalized to 30 days |
| F | 29 | Pfizer | Supraclavicular ipsilateral to vaccine injection | Day after first dose vaccine, supraclavicular swelling and pain present | None | 2 | Subcentimetric | Round | No evidence hilum | Prevalent hard pattern | Central and peripheral vascular signals | Normalized to 30 days |
| F | 66 | Moderna | Supraclavicular ipsilateral to vaccine injection | Occasionally, 2 weeks after second dose, during shoulder rm | None | 2 | Around 1.0 cm | Ovular | Assimetric cortical thickening with hilum evidence | Stiffness similar to surrounding tissue | Central and peripheral vascular signals | Normalized to 30 days |
| M | 59 | Astrazeneca | Supraclavicular ipsilateral to vaccine injection | Occasionally, autopalpation 4 days after second dose vaccine | None | 2 | 0.7 and 1.2 cm | Ovular | Asimetric cortical thickening with hilum evidence | Stiffness similar to surrounding tissue | Normal | Unnecessary other follow-up |